Aflibercept for Diabetic Macular Edema In Real-life Practice in GREece

ADMIRE was a prospective, observational cohort study of patients with diabetic macular edema (DME). Efficacy was assessed by change in best-corrected visual acuity (BCVA) and central retinal thickness (CRT) from baseline to months 12, 24 and 36 after treatment with intravitreal aflibercept in treatment-naïve patients and previously treated patients. Safety was evaluated by recording any patients-reported events.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Diabetic Macular Edema

Age range

45 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

University of Athens

Athens, 12462, Greece

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients with DM, able to give written informed consent Patients with DME>320 μm, who need treatment

Exclusion criteria

Patients with other retinal diseases than DME Intraocular surgery within the last 6 months

Treatment and study plan

aflibercept

Drug

Intravitreal aflibercept as used in the routice clinical practice

Primary outcomes

Change in best-corrected visual acuity

Time frame: 12 months

Sponsors and collaborators

Lead sponsor

University of Athens

Other

Registry information

Official study title

Aflibercept for Diabetic Macular Edema In Real-life Practice in GREece: The ADMIRE Study

Acronym: ADMIRE

Important dates

Study start: 2019
Primary completion: 2021
Study completion: 2022
First posted: Jan 13, 2023
Registry last updated: Jan 13, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed